PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 Vaccine

GOLDEN, Colo. — April 14, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free injection system will be used to deliver a COVID-19 vaccine being developed by Immunomic Therapeutics, Inc. (ITI). ITI is a clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms using the body’s natural biochemistry to generate a broad immune response. The vaccine candidate against COVID-19 will leverage their investigational UNiversal Intracellular Targeted Expression (UNITETM) platform.

Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE Platform

ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO — April 09, 2020 — Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus.

PharmaJet Announces Appointment of Pharmaceutical Executive Dr. Marie Mazur to the Board of Directors

GOLDEN, Colo. — March 25, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Dr. Marie Mazur, has been appointed to its Board of Directors. Dr. Mazur is a global business executive with over 30 years of experience growing revenue and profits for major vaccine and pharmaceutical companies.

Ron Lowy, Executive Chairman, PharmaJet Inc. said, “we are very pleased to welcome Dr. Mazur to the PharmaJet Board of Directors."

PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-free Delivery Devices

GOLDEN, Colo. — March 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding the use of needle-free technology to further progress promising nucleic acid vaccines, while also funding the development of PharmaJet’s next generation needle-free devices.

Vaccine

Vaccine publishes independent survey showing overwhelming preference for Needle-free technology in large-scale intradermal polio vaccination campaign

The campaign, sponsored by the World Health Organization as part of its polio eradication efforts, vaccinated 500,000 children, aged 4 – 59 months, over a one-week period in early 2019.  Data on acceptability of the PharmaJet Tropis Needle-Free Injection System was collected from 610 vaccinators and 4,898 caregivers.  Of those with prior needle and syringe…

First large-scale polio vaccination campaign using PharmaJet intradermal Needle-free Injector

GOLDEN, Colo. — February 5, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the publication of independent survey results from the first large-scale campaign using its needle-free technology. The paper, entitled Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, was published in Vaccine on January 23, 2020.

Study published in Clinical Cancer Research cites important progress towards new treatments for cancer using PharmaJet Tropis

Invectys published the results of their Phase I clinical trial testing their immune-therapeutic DNA cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system (Teixeira et al, 2019). The publication cites that “administration with the PharmaJet Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients.

Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector

GOLDEN, Colo. — January 8, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published. The study entitled A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors was published in Clinical Cancer Research on November 19, 2019.

PharmaJet Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors

GOLDEN, Colo. — December 17, 2019 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Kevin L. Lorenz, J.D., has been appointed to its Board of Directors. Mr. Lorenz, Chief Investment Officer, Senior Vice President, Treasury and Private Investments at the Katz Group, is an accomplished executive with over 25 years of experience guiding and implementing investment strategy across public and private companies.

Study published in Viruses shows superior response with PharmaJet Tropis over electroporation

Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response.